Jazz Pharmaceuticals (JAZZ) Misses Q2 EPS by 47c; raises guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $214.44 --0%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
DD, ARDS, OMID, More
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
DD, ARDS, OMID, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $5.71, $0.47 worse than the analyst estimate of $6.18. Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1.11 billion.
GUIDANCE:
Jazz Pharmaceuticals sees FY2026 revenue of $4.600-4.750 billion, versus the consensus of $4.512 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 3c; Offers Guidance
- Gartner, Inc. (IT) Tops Q3 EPS by 75c, Beats on Revenue
- i-80 Gold Corp. (IAUX) Misses Q3 EPS by 5c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
